Cancer-related fatigue: An updated systematic review of its management by Minton, O et al.
58 EUROPEAN JOURNAL OF PALLIATIVE CARE, 2014; 21(2)
Clinical  management www.ejpc.eu.com
F
atigue is a consistent problem for most,
if not all, patients with advanced
cancer.1 Its exact mechanisms are
unclear and this means that available
treatments are non-specific.1 In this article, 
we will discuss the role of drug and non-drug
interventions and the evidence from meta-
analyses regarding their effectiveness and
potential use in clinical practice. 
Method
For this article, we conducted an updated
review of management for fatigue which uses
data from three relevant Cochrane systematic
reviews.2–4 Two of them specifically looked at
cancer-related fatigue,2,4 while the authors of
the other one examined fatigue in palliative
care patients regardless of diagnosis.3
We also conducted a Medline search using
the key search terms ‘fatigue’, ‘neoplasms’ and
‘palliative care’. This was conducted up to the
beginning of May 2013. The detailed search
terms and methods can be found in the
relevant reviews2–4 on the Cochrane Library
website (www.thecochranelibrary.com). 
It is worth noting that there have been over
170 clinical trials conducted in the area of
cancer-related fatigue. However, the
heterogeneous populations and variety of
outcome measures used have meant that
synthesising the data has not always been
possible. It is equally fair to say that a meta-
analysis cannot necessarily provide guidance
on individual patient management. 
In this article, we will separately discuss the
role of drugs and exercise in the management
of cancer-related fatigue, before making
overall recommendations for clinical practice.
The role of drugs
Recent drug research has focused on
psychostimulants, namely methylphenidate
and modafinil. There has also been some
further examination of antidepressants but,
while these drugs were found to improve
mood, they showed no effect on fatigue.2 The
role of corticosteroids was examined by the
authors of the review investigating fatigue in
palliative care patients.3 However, despite the
widespread clinical use and anecdotal benefit,
there are no corresponding studies to support
the effectiveness of these drugs. 
We examined the increased evidence
supporting the use of methylphenidate. There
are now eight randomised controlled trials
(RCTs) published.5 These trials are mainly in
patients with advanced disease and mixed
tumour types but also include patients
receiving chemotherapy.
The picture is mixed, with only two trials
out of eight demonstrating superiority of
methylphenidate over placebo. These two
trials include the one with the largest sample
size and longest follow-up. The limitations of
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many of the other trials are small
sample sizes and a short
follow-up duration (two
weeks or less). 
In the combined 
meta-analysis,5 the total sample size
is 710 and the overall effect size of
the standardised mean difference
is -0.22 (95% confidence interval
[CI] -0.38 to -0.06; p=0.007);
710 is a reasonable number of
patients, but a variety of
dosing regimens and outcome
measures were used. 
Methylphenidate cannot be
recommended for routine clinical use
without further positive trials but
equally, based on the current evidence, we
cannot dismiss its role. A larger trial with a
longer follow-up (four weeks or more) and a
minimum dosage of 20 mg is required to make
more definitive conclusions. Four weeks and
20 mg are the mean duration of treatment and
dose from the eight trials; the positive trials
had both a longer treatment duration and
higher dose. It is worth noting that
methylphenidate trials did not demonstrate
an overall statistically significant increase in
adverse events over placebo. This suggests that
methylphenidate use should not be limited
because of a fear of side effects.
On the other hand, based on two RCTs,6,7
it appears that there is little or no evidence
supporting the role of modafinil in cancer
fatigue. One trial was conducted in a mixed
tumour group with patients on
chemotherapy,6 the other in advanced lung
cancer with patients off treatment.7 The total
sample size is 790, the overall effect size is 
-0.06 (95% CI -0.20 to -0.08; p= 0.73). This
indicates no statistically significant effect over
placebo. There was a subgroup analysis from
the first trial6 that indicated a positive effect of
modafinil in severe fatigue (based on a score of
8 or more on a 0–10 numerical rating scale). It
is difficult to translate this isolated finding
into a recommendation for practice. The
authors of the advanced lung cancer study7
demonstrated no change in outcomes based
on a subanalysis of baseline fatigue and
performance status. They did demonstrate a
clinically significant improvement in fatigue
scores in both patient groups (who had
received either placebo or modafinil after
unblinding). A number of secondary analyses
on mood and sleepiness ratings failed to
demonstrate a difference between the two
groups – but, once again, an improvement
was seen in both. There was no
overall statistically significant
increase in adverse events
compared with placebo.
However, despite these
results and the use of
appropriately powered
trials, the lack of effect
means modafinil cannot be
recommended for routine
clinical use. 
The Cochrane review by
Peuckmann et al3 focused on drugs for fatigue
in palliative care generally. There is little data
from any conditions other than cancer that
could influence practice. The absolute
numbers were very small and the quality of
the trials was poor. It was not possible to
produce any meta-analysis. The authors
concluded there was no evidence supporting
the use of modafinil in multiple sclerosis, but
that there was possibly a role for amantadine
(an antiretroviral drug). However, this was
based on low-quality evidence and has not
been adopted in practice. Overall, no
recommendations for practice can be made
from these findings. 
The role of exercise 
The role of exercise in relieving cancer fatigue
has recently been evaluated in a Cochrane
systematic review.4 The meta-analysis
involving nearly 3,000 participants found
evidence in favour of exercise with an overall
effect size of -0.27 (95% CI -0.37 to -0.17). 
This is an impressive overall size, but it does
mask specific problems related to trial quality
and contamination between groups
undergoing interventions. There are also some
specific exclusions to these observed benefits.
The research has mainly been carried out in
patients with breast and prostate cancer and
in those receiving treatment. There has been
little or no examination in patients with
advanced disease. It is also important to note
that only aerobic exercise had an effect –
resistance training did not. 
Once again, it is difficult to translate the
effect size into recommendations for practice.
There are no suggestions from the review
authors about the optimum frequency,
duration or intensity of the exercise regimen
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to be used. There may also be a resource issue
if the exercise programme needs to be
supervised. It is, however, interesting to note
that the overall effect size is larger than that
demonstrated in the methylphenidate studies.
In a research setting, it may be worth
exploring a combined regimen of drug and
exercise. There were non-specific benefits
noted from many of the secondary trial
outcomes in terms of reduced pain, improved
mood and reduced sleep disturbance. There
were no adverse outcomes specifically
reported in the populations studied. 
Discussion
While it is encouraging to see an increase in
the volume of trials, there is no clear
agreement on recommendations for clinical
practice from the research. This may be partly
because the interventions used in the studies 
– for example, the exercise interventions – are
not standardised. 
It is worth identifying the clinical
phenotype of patients who might benefit and
when. There is a suggestion that
pharmacological interventions result in a
greater response in patients with more severe
fatigue, but the evidence is not sufficiently
solid to draw any conclusion. Screening
patients regularly would help to identify those
who may benefit from treatment. 
A better understanding of the underlying
pathophysiology of fatigue would help to
generate directions for future clinical trials.8
If we had a more detailed
understanding of the
mechanism for cancer fatigue,
we might be able to design
more targeted treatments. Our
current understanding is that
fatigue is driven by a pro-inflammatory
cytokine response.1 These cytokines may
cause diverse effects, including alterations in
muscle function and the blood–brain barrier.
Modulation of these pathways may result in
improvement. Numerous monoclonal
antibodies are now commercially available
and could form the basis of future clinical
trials. These trials also ought to include a
mechanistic component with storing of
serum for subsequent analysis. This is a
routine approach undertaken in the vast
majority of cancer treatment trials. 
Finally, it is also worth noting that in
advanced cancer, fatigue rarely occurs in
isolation.9 A subset analysis of a large
European study of patients with advanced
cancer demonstrated fatigue associated with
mood and sleep disturbances and increased
pain. However, there was no link to cachexia
or non-specific inflammatory markers such as
C-reactive protein.
Conclusions 
There is sufficient evidence to encourage
exercise to alleviate fatigue in cancer patients,
particularly in those with earlier disease or on
active treatment, but no recommendation can
be made about frequency, duration or
intensity. Further clinical trials are needed to
investigate the potential benefits of
methylphenidate. An agreement on the
clinical characteristics and severity of cancer
fatigue would allow clinicians to determine
which patients are most likely to respond.
A greater understanding of the biology of
cancer fatigue would allow researchers to
develop more targeted treatments. At the
moment, we are in a somewhat disappointing
position, given the increasing number of
clinical trials and the impact of fatigue in
advanced cancer. 
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